International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Launched by PROSTATE CANCER CLINICAL TRIALS CONSORTIUM · May 11, 2017
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The International Registry for Men With Advanced Prostate Cancer (IRONMAN) is a study designed to gather information from at least 5,000 men diagnosed with advanced prostate cancer. This includes men with specific types of advanced cancer that have spread or are likely to spread. The aim is to learn more about how treatment and care differ across various countries and healthcare settings, helping to improve outcomes for patients. The study will take place in multiple countries, including the United States, Canada, Australia, and several others.
To participate, men must be 21 years or older and have a confirmed diagnosis of prostate cancer. They should not have any other major cancers that require treatment. Participants will be asked to provide information about their health and treatment over at least five years, including filling out questionnaires every three months. Blood samples will also be collected to help researchers understand how the disease responds to different treatments. This study not only aims to improve treatment but also hopes to identify markers that can predict how well patients will respond to therapy.
Gender
MALE
Eligibility criteria
- • • Willing and able to provide written informed consent and privacy authorization for the release of personal health information.
- • NOTE: Privacy authorization may be either included in the informed consent or obtained separately.
- • Males 21 years of age and above
- • Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA \>20ng/mL at the time of initial prostate cancer diagnosis
- • No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin
About Prostate Cancer Clinical Trials Consortium
The Prostate Cancer Clinical Trials Consortium is a leading organization dedicated to advancing the understanding and treatment of prostate cancer through innovative clinical research. Comprising a network of esteemed academic institutions and research centers, the consortium facilitates collaborative efforts to design and implement rigorous clinical trials aimed at evaluating novel therapies and treatment strategies. By fostering partnerships among researchers, clinicians, and industry stakeholders, the consortium strives to improve patient outcomes and enhance the quality of care for individuals affected by prostate cancer. Its commitment to scientific excellence and patient-centered research positions it at the forefront of efforts to combat this prevalent disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Houston, Texas, United States
New Haven, Connecticut, United States
New York, New York, United States
Chicago, Illinois, United States
New York, New York, United States
Vancouver, British Columbia, Canada
Worcester, Massachusetts, United States
Jacksonville, Florida, United States
New York, New York, United States
Jackson, Mississippi, United States
Cape Town, , South Africa
Tampa, Florida, United States
Boston, Massachusetts, United States
Seattle, Washington, United States
Durham, North Carolina, United States
Madison, Wisconsin, United States
Chapel Hill, North Carolina, United States
Durham, North Carolina, United States
Philadelphia, Pennsylvania, United States
Gainesville, Florida, United States
Atlanta, Georgia, United States
Madrid, , Spain
Detroit, Michigan, United States
Basel, , Switzerland
Zürich, , Switzerland
Charlottesville, Virginia, United States
Dublin, , Ireland
San Diego, California, United States
Madrid, , Spain
Memphis, Tennessee, United States
Baltimore, Maryland, United States
Barcelona, , Spain
Valencia, , Spain
Atlanta, Georgia, United States
Chicago, Illinois, United States
Los Angeles, California, United States
Nairobi, , Kenya
Woolloongabba, Queensland, Australia
Hamilton, Ontario, Canada
Sydney, New South Wales, Australia
Melbourne, Victoria, Australia
Northwood, Middlesex, United Kingdom
Málaga, , Spain
New Orleans, Louisiana, United States
New York, New York, United States
Charleston, South Carolina, United States
Northwood, , United Kingdom
Cleveland, Ohio, United States
Madrid, , Spain
Cardiff, , United Kingdom
London, , United Kingdom
Sunderland, , United Kingdom
Johannesburg, Gauteng, South Africa
Birmingham, Alabama, United States
Toronto, Ontario, Canada
Oviedo, , Spain
Chicago, Illinois, United States
Chur, , Switzerland
Stevenage, , United Kingdom
Cardiff, , United Kingdom
Castellón De La Plana, , Spain
Manchester, , United Kingdom
örebro, , Sweden
Madison, Wisconsin, United States
Ilorin, , Nigeria
Portland, Oregon, United States
Buffalo, New York, United States
Wirral, , United Kingdom
Memphis, Tennessee, United States
Montréal, Quebec, Canada
Bellinzona, , Switzerland
Lancaster, , United Kingdom
Brooklyn, New York, United States
Toronto, Ontario, Canada
Saint Gallen, , Switzerland
Preston, , United Kingdom
Ann Arbor, Michigan, United States
Dekalb, Illinois, United States
Geneva, Illinois, United States
Warrenville, Illinois, United States
Towson, Maryland, United States
Buffalo, New York, United States
Durham, North Carolina, United States
Doylestown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
West Reading, Pennsylvania, United States
Columbia, South Carolina, United States
Herston, Brisbane, Australia
Darlinghurst, New South Wales, Australia
Sydney, New South Wales, Australia
Cleveland, Queensland, Australia
Box Hill, Victoria, Australia
Mount Waverley, Victoria, Australia
Melbourne N., , Australia
Melbourne, , Australia
Bela Vista, São Paulo, Brazil
Curitiba, , Brazil
Porto Alegre, , Brazil
São Paulo, , Brazil
São Paulo, , Brazil
Edmonton, Alberta, Canada
Ottawa, Ontario, Canada
Québec, Quebec, Canada
Dublin, Leinster, Ireland
Dublin, , Ireland
Sligo, , Ireland
Abeokuta, , Nigeria
Lagos, , Nigeria
Maiduguri, , Nigeria
Oslo, , Norway
Barcelona, Catalunya, Spain
Badalona, , Spain
Barcelona, , Spain
Zaragoza, , Spain
Malmö, Skane, Sweden
Umeå, , Sweden
Southampton, Hampshire, United Kingdom
London, , United Kingdom
Sheffield, , United Kingdom
South Shields, , United Kingdom
Zürich, , Switzerland
Bridgetown, , Barbados
Bento Gonçalves, Rio Grande Do Sul, Brazil
Kingston, , Jamaica
Pretoria, Gauteng, South Africa
Tuscaloosa, Alabama, United States
Bela Vista, , Brazil
Patients applied
Trial Officials
Daniel George, MD
Principal Investigator
Duke Cancer Institute
Lorelei Mucci, ScD
Principal Investigator
Harvard School of Public Health (HSPH)
Phillip Kantoff, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials